Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Helix Biopharma Corp T.HBP

Alternate Symbol(s):  HBPCF

Healthcare Biotechnology
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant... see more

Recent & Breaking News (TSX:HBP)

Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development

TheNewsWire September 1, 2022

Helix Biopharma Corp. Announces Conclusion of Funding Agreement with Lind Global Macro Fund LP

TheNewsWire August 30, 2022

Helix BioPharma Corp. Announces Scientific Collaboration with University Hospital Tuebingen

TheNewsWire August 9, 2022

Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.

Accesswire April 22, 2022

Helix Biopharma Corp. Closes Private Placement

Accesswire April 21, 2022

Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

Accesswire April 18, 2022

Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription

Accesswire April 13, 2022

Helix Announces Board Resignation

Accesswire April 7, 2022

Helix Biopharma Corp. Announces Management and Board Changes

Accesswire March 22, 2022

Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

Accesswire March 16, 2022

Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board

Accesswire March 16, 2022

CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

Accesswire March 11, 2022

Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

Accesswire March 11, 2022

Helix BioPharma Corp. Reports Voting Results and Appointment of New Board Director

Accesswire January 28, 2022

Helix BioPharma Corp. Provides Corporate Update

Accesswire December 31, 2021

Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

Accesswire December 15, 2021

Helix BioPharma Corp. Extends Period to Exercise Warrants

Accesswire December 13, 2021

Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results

Accesswire December 9, 2021

Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update

Accesswire November 30, 2021

Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update

Accesswire November 15, 2021